Page last updated: 2024-10-28

hydroxyurea and Fatigue

hydroxyurea has been researched along with Fatigue in 7 studies

Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.

Research Excerpts

ExcerptRelevanceReference
"This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine arabinoside) in adults with untreated acute myelogenous leukemia or high-risk myelodysplastic syndrome."9.19Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p ( Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R, 2014)
"This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine arabinoside) in adults with untreated acute myelogenous leukemia or high-risk myelodysplastic syndrome."5.19Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p ( Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R, 2014)
" Adverse events were primarily grades 1/2 with no unexpected safety signals."2.84The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). ( Byrne, J; Garg, M; Habr, D; Hasan, Y; Hunter, D; Jones, MM; Koschmieder, S; Lyons, R; Martino, B; Mesa, R; Passamonti, F; Rinaldi, C; Vannucchi, AM; Verstovsek, S; Yacoub, A; Zachee, P; Zhen, H, 2017)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bertolini, F1
Cassisa, A1
Miggiano, MC1
Gasparin, P1
Willemze, R1
Suciu, S1
Muus, P1
Halkes, CJ1
Meloni, G1
Meert, L1
Karrasch, M1
Rapion, J1
Vignetti, M1
Amadori, S1
de Witte, T1
Marie, JP1
Stein, BL1
Moliterno, AR1
Tiu, RV1
Geyer, H1
Scherber, R1
Kosiorek, H1
Dueck, AC1
Kiladjian, JJ1
Xiao, Z1
Slot, S1
Zweegman, S1
Sackmann, F1
Fuentes, AK1
Hernández-Maraver, D1
Döhner, K1
Harrison, CN1
Radia, D1
Muxi, P1
Besses, C1
Cervantes, F1
Johansson, PL1
Andreasson, B1
Rambaldi, A1
Barbui, T1
Bonatz, K1
Reiter, A1
Boyer, F1
Etienne, G1
Ianotto, JC1
Ranta, D1
Roy, L1
Cahn, JY1
Maldonado, N1
Barosi, G1
Ferrari, ML1
Gale, RP1
Birgegard, G1
Xu, Z1
Zhang, Y1
Sun, X1
Xu, J1
Zhang, P1
te Boekhorst, PA1
Commandeur, S1
Schouten, H1
Pahl, HL1
Griesshammer, M1
Stegelmann, F1
Lehmann, T1
Senyak, Z1
Vannucchi, AM2
Passamonti, F2
Samuelsson, J1
Mesa, RA1
Mesa, R1
Yacoub, A1
Zachee, P1
Garg, M1
Lyons, R1
Koschmieder, S1
Rinaldi, C1
Byrne, J1
Hasan, Y1
Verstovsek, S1
Hunter, D1
Jones, MM1
Zhen, H1
Habr, D1
Martino, B1
Vogler, S1
Burkhard, R1
Cortes, J1
Kantarjian, H1
O'Brien, S1
Robertson, LE1
Pierce, S1
Talpaz, M1

Reviews

1 review available for hydroxyurea and Fatigue

ArticleYear
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
    Annals of hematology, 2014, Volume: 93, Issue:12

    Topics: Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cost of Illness; Disease Progression

2014

Trials

3 trials available for hydroxyurea and Fatigue

ArticleYear
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p
    Annals of hematology, 2014, Volume: 93, Issue:6

    Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides

2014
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).
    British journal of haematology, 2017, Volume: 176, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Cross-Over Studies; Double-Blind Method; Drug Substitution; Fatigue;

2017
Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.
    The American journal of medicine, 1996, Volume: 100, Issue:4

    Topics: Age Factors; Aged; Antineoplastic Agents; Basophils; Bone Marrow; Chronic Disease; Fatigue; Follow-U

1996

Other Studies

3 other studies available for hydroxyurea and Fatigue

ArticleYear
Skin nodules in onset of acute myeloid leukemia, a myelomonocytic variant case.
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2017, Volume: 152, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cytarabine; Daunorubicin; Delayed Diagnosis;

2017
Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Jan-10, Volume: 34, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Fatigue; Female; Fever; Humans; Hydroxyurea;

2016
[A 69-year-old man with deep fatigue, weight loss and eosinophilia].
    Praxis, 2005, Nov-02, Volume: 94, Issue:44

    Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Diagnosis, Differential; Fatigue; Follow-Up St

2005